Laura Mezquita1, Edouard Auclin2, Roberto Ferrara1, Melinda Charrier3, Jordi Remon1, David Planchard1, Santiago Ponce4, Luis Paz Ares4, Laura Leroy5, Clarisse Audigier-Valette6, Enriqueta Felip7, Jorge Zerón-Medina7, Pilar Garrido8, Solenn Brosseau9, Gérard Zalcman9, Julien Mazieres10, Caroline Caramela11, Jihene Lahmar1, Julien Adam12, Nathalie Chaput3,13, Jean Charles Soria14,15, Benjamin Besse1,15. 1. Medical Oncology Department, Gustave Roussy, Villejuif, France. 2. Medical and Gastrointestinal Oncology Department, Hôpital Européen Georges Pompidou, Paris, France. 3. Laboratory of Immunomonitoring in Oncology, UMS 3655 CNRS/US 23 INSERM, Gustave Roussy, Villejuif, France. 4. Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain. 5. Medical Oncology Department, Institut Bergonie, Bordeaux, France. 6. Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, France. 7. Medical Oncology Department, Hospital Vall d'Hebron, Barcelona, Spain. 8. Medical Oncology Department, Hospital Ramón y Cajal, Madrid, Spain. 9. Thoracic Oncology Department, CIC1425/CLIP2 Paris-Nord, Hôpital Bichat-Claude Bernard, Paris, France. 10. Medical Oncology Department, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. 11. Radiology Department, Gustave Roussy, Villejuif, France. 12. Pathology Department, Gustave Roussy, Villejuif, France. 13. Faculty of Pharmacy, University Paris-Saclay, Chatenay-Malabry, France. 14. Drug Development Department, Gustave Roussy, Villejuif, France. 15. Faculty of Medicine, University Paris-Saclay, Le Kremlin Bicêtre, France.
Abstract
IMPORTANCE: Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) outcomes in patients with melanoma. OBJECTIVE: To determine whether pretreatment dNLR and LDH are associated with resistance to ICIs in patients with advanced non-small cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective study with a test (n = 161) and a validation set (n = 305) treated with programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors in 8 European centers, and a control cohort (n = 162) treated with chemotherapy only. Complete blood cell counts, LDH, and albumin levels were measured before ICI treatment. A lung immune prognostic index (LIPI) based on dNLR greater than 3 and LDH greater than upper limit of normal (ULN) was developed, characterizing 3 groups (good, 0 factors; intermediate, 1 factor; poor, 2 factors). MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS). Secondary end points were progression-free survival (PFS) and disease control rate (DCR). RESULTS: In the pooled ICI cohort (N = 466), 301 patients (65%) were male, 422 (90%) were current or former smokers, and 401 (87%) had performance status of 1 or less; median age at diagnosis was 62 (range, 29-86) years; 270 (58%) had adenocarcinoma and 159 (34%) had squamous histologic subtype. Among 129 patients with PD-L1 data, 96 (74%) had PD-L1 of at least 1% by immunohistochemical analysis, and 33 (26%) had negative results. In the test cohort, median PFS and OS were 3 (95% CI, 2-4) and 10 (95% CI, 8-13) months, respectively. A dNLR greater than 3 and LDH greater than ULN were independently associated with OS (hazard ratio [HR] 2.22; 95% CI, 1.23-4.01 and HR, 2.51; 95% CI, 1.32-4.76, respectively). Median OS for poor, intermediate, and good LIPI was 3 months (95% CI, 1 month to not reached [NR]), 10 months (95% CI, 8 months to NR), and 34 months (95% CI, 17 months to NR), respectively, and median PFS was 2.0 (95% CI, 1.7-4.0), 3.7 (95% CI, 3.0-4.8), and 6.3 (95% CI, 5.0-8.0) months (both P < .001). Disease control rate was also correlated with dNLR greater than 3 and LDH greater than ULN. Results were reproducible in the ICI validation cohort for OS, PFS, and DCR, but were nonsignificant in the chemotherapy cohort. CONCLUSIONS AND RELEVANCE: Pretreatment LIPI, combining dNLR greater than 3 and LDH greater than ULN, was correlated with worse outcomes for ICI, but not for chemotherapy, suggesting that LIPI can serve as a potentially useful tool when selecting ICI treatment, raising the hypothesis that the LIPI might be useful for identifying patients unlikely to benefit from treatment with an ICI.
IMPORTANCE: Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) outcomes in patients with melanoma. OBJECTIVE: To determine whether pretreatment dNLR and LDH are associated with resistance to ICIs in patients with advanced non-small cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective study with a test (n = 161) and a validation set (n = 305) treated with programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors in 8 European centers, and a control cohort (n = 162) treated with chemotherapy only. Complete blood cell counts, LDH, and albumin levels were measured before ICI treatment. A lung immune prognostic index (LIPI) based on dNLR greater than 3 and LDH greater than upper limit of normal (ULN) was developed, characterizing 3 groups (good, 0 factors; intermediate, 1 factor; poor, 2 factors). MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS). Secondary end points were progression-free survival (PFS) and disease control rate (DCR). RESULTS: In the pooled ICI cohort (N = 466), 301 patients (65%) were male, 422 (90%) were current or former smokers, and 401 (87%) had performance status of 1 or less; median age at diagnosis was 62 (range, 29-86) years; 270 (58%) had adenocarcinoma and 159 (34%) had squamous histologic subtype. Among 129 patients with PD-L1 data, 96 (74%) had PD-L1 of at least 1% by immunohistochemical analysis, and 33 (26%) had negative results. In the test cohort, median PFS and OS were 3 (95% CI, 2-4) and 10 (95% CI, 8-13) months, respectively. A dNLR greater than 3 and LDH greater than ULN were independently associated with OS (hazard ratio [HR] 2.22; 95% CI, 1.23-4.01 and HR, 2.51; 95% CI, 1.32-4.76, respectively). Median OS for poor, intermediate, and good LIPI was 3 months (95% CI, 1 month to not reached [NR]), 10 months (95% CI, 8 months to NR), and 34 months (95% CI, 17 months to NR), respectively, and median PFS was 2.0 (95% CI, 1.7-4.0), 3.7 (95% CI, 3.0-4.8), and 6.3 (95% CI, 5.0-8.0) months (both P < .001). Disease control rate was also correlated with dNLR greater than 3 and LDH greater than ULN. Results were reproducible in the ICI validation cohort for OS, PFS, and DCR, but were nonsignificant in the chemotherapy cohort. CONCLUSIONS AND RELEVANCE: Pretreatment LIPI, combining dNLR greater than 3 and LDH greater than ULN, was correlated with worse outcomes for ICI, but not for chemotherapy, suggesting that LIPI can serve as a potentially useful tool when selecting ICI treatment, raising the hypothesis that the LIPI might be useful for identifying patients unlikely to benefit from treatment with an ICI.
Authors: Arnoud J Templeton; Olga Ace; Mairéad G McNamara; Mustafa Al-Mubarak; Francisco E Vera-Badillo; Thomas Hermanns; Boštjan Seruga; Alberto Ocaña; Ian F Tannock; Eitan Amir Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-03 Impact factor: 4.254
Authors: Ondrej Fiala; Milos Pesek; Jindrich Finek; Ondrej Topolcan; Jaroslav Racek; Martin Svaton; Radek Kucera; Marek Minarik; Lucie Benesova; Zbynek Bortlicek; Renata Chloupkova; Alexandr Poprach; Tomas Buchler Journal: Anticancer Res Date: 2016-05 Impact factor: 2.480
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Julia Kargl; Stephanie E Busch; Grace H Y Yang; Kyoung-Hee Kim; Mark L Hanke; Heather E Metz; Jesse J Hubbard; Sylvia M Lee; David K Madtes; Martin W McIntosh; A McGarry Houghton Journal: Nat Commun Date: 2017-02-01 Impact factor: 14.919
Authors: Kim E M van Kessel; Lorraine M de Haan; Elisabeth E Fransen van de Putte; Bas W G van Rhijn; Ronald de Wit; Michiel S van der Heijden; Ellen C Zwarthoff; Joost L Boormans Journal: Bladder Cancer Date: 2016-07-27
Authors: Juan Ruiz-Bañobre; María C Areses-Manrique; Joaquín Mosquera-Martínez; Alexandra Cortegoso; Francisco J Afonso-Afonso; Noemí de Dios-Álvarez; Natalia Fernández-Núñez; Cristina Azpitarte-Raposeiras; Margarita Amenedo; Lucía Santomé; José Luis Fírvida-Pérez; Rosario García-Campelo; Jorge García-González; Joaquín Casal-Rubio; Sergio Vázquez Journal: Transl Lung Cancer Res Date: 2019-12